SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-17-001191
Filing Date
2017-02-10
Accepted
2017-02-10 16:17:10
Documents
59
Period of Report
2016-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q1216_relmadatherap.htm 10-Q 374254
2 AMENDMENT NO. 2 TO RELMADA THERAPEUTICS, INC. 2014 STOCK OPTION AND EQUITY INCEN f10q1216ex10i_relmadatherap.htm EX-10.1 5859
3 CERTIFICATION f10q1216ex31i_relmadatherap.htm EX-31.1 20440
4 CERTIFICATION f10q1216ex31ii_relmadatherap.htm EX-31.2 19019
5 CERTIFICATION f10q1216ex32i_relmadatherap.htm EX-32.1 8247
6 CERTIFICATION f10q1216ex32ii_relmadatherap.htm EX-32.2 8913
  Complete submission text file 0001213900-17-001191.txt   3018823

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE FILE rlmd-20161231.xml EX-101.INS 528416
8 XBRL SCHEMA FILE rlmd-20161231.xsd EX-101.SCH 31540
9 XBRL CALCULATION FILE rlmd-20161231_cal.xml EX-101.CAL 26065
10 XBRL DEFINITION FILE rlmd-20161231_def.xml EX-101.DEF 145957
11 XBRL LABEL FILE rlmd-20161231_lab.xml EX-101.LAB 330030
12 XBRL PRESENTATION FILE rlmd-20161231_pre.xml EX-101.PRE 229337
Mailing Address 275 MADISON AVENUE, SUITE 702 NEW YORK NY 10016
Business Address 275 MADISON AVENUE, SUITE 702 NEW YORK NY 10016 646-677-3853
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55347 | Film No.: 17593507
SIC: 2834 Pharmaceutical Preparations